関連する実験動画
Updated: Jan 7, 2026

05:17
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
1.9K
持続可能な医薬品複素環設計におけるソノケミストリー:進歩と抗がん作用
Priteeparna Das1, Vijayakumar Hemamalini2, N Pawar1
1Department of Industrial and Engineering Chemistry, Institute of Chemical Technology, Indian Oil Odisha Campus, Samantapuri, Bhubaneswar, Odisha 751013, India.
Bioorganic chemistry
|December 28, 2025
まとめ
超音波支援合成は、抗がん複素環化合物を生成するための持続可能な方法を提供します。このアプローチは、医薬品化学における反応を加速し、収率を向上させ、エネルギーと危険な溶媒の使用を削減します。
背景:
- 超音波支援合成は、持続可能で効率的な合成戦略のための強力なツールです。
- 窒素、硫黄、酸素を含む複素環は、医薬品化学における重要な骨格であり、いくつかは抗がん活性を示します。
- 最近、これらの貴重な複素環化合物の合成に超音波エネルギーを利用することに注目が集まっています。
結論:
- 超音波支援合成は、貴重な複素環骨格への持続可能で効率的なルートを提供します。
- この方法論は、従来の技術よりも大きな利点を提供し、グリーンケミストリーの原則に沿っています。
- 合成された複素環は有望な抗がんの可能性を示しており、さらなる調査が保証されます。
関連する概念動画
Cycloaddition Reactions: Overview
3.3K
Cycloadditions are one of the most valuable and effective synthesis routes to form cyclic compounds. These are concerted pericyclic reactions between two unsaturated compounds resulting in a cyclic product with two new σ bonds formed at the expense of π bonds. The [4 + 2] cycloaddition, known as the Diels–Alder reaction, is the most common. The other example is a [2 + 2] cycloaddition.
3.3K
Structure-Activity Relationships and Drug Design
1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K
Reduction of Alkenes: Asymmetric Catalytic Hydrogenation
3.8K
Catalytic hydrogenation of alkenes is a transition-metal catalyzed reduction of the double bond using molecular hydrogen to give alkanes. The mode of hydrogen addition follows syn stereochemistry.
The metal catalyst used can be either heterogeneous or homogeneous. When hydrogenation of an alkene generates a chiral center, a pair of enantiomeric products is expected to form. However, an enantiomeric excess of one of the products can be facilitated using an enantioselective reaction or an...
The metal catalyst used can be either heterogeneous or homogeneous. When hydrogenation of an alkene generates a chiral center, a pair of enantiomeric products is expected to form. However, an enantiomeric excess of one of the products can be facilitated using an enantioselective reaction or an...
3.8K
Diels–Alder Reaction Forming Cyclic Products: Stereochemistry
4.6K
The Diels–Alder reaction is one of the robust methods for synthesizing unsaturated six-membered rings. The reaction involves a concerted cyclic movement of six π electrons: four π electrons from the diene and two π electrons from the dienophile.
4.6K
Diels–Alder Reaction Forming Bridged Bicyclic Products: Stereochemistry
5.3K
Diels–Alder reactions between cyclic dienes locked in an s-cis configuration and dienophiles yield bridged bicyclic products.
5.3K
Electron Transport Chain: Complex I and II
18.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.3K
![Solid-phase Synthesis of [4.4] Spirocyclic Oximes](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58508.jpg&w=3840&q=50)
